Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of ORAMED PHARMACEUTICALS INC. from 30 Nov 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
ORAMED PHARMACEUTICALS INC. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 30 Nov 2010 to 30 Sep 2025.
  • ORAMED PHARMACEUTICALS INC. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Sep 2025 was $59,451,000.
  • ORAMED PHARMACEUTICALS INC. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 30 Sep 2025 was $55,744,000.
  • ORAMED PHARMACEUTICALS INC. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $15,920,000, a 413% decline from 2023.
  • ORAMED PHARMACEUTICALS INC. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $5,088,000.
  • ORAMED PHARMACEUTICALS INC. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $37,664,000.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

ORAMED PHARMACEUTICALS INC. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $55,744,000 $59,451,000 +$77,960,000 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $22,216,000 $13,134,000 +$2,296,000 +21% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $24,512,000 $7,058,000 -$8,592,000 -560% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $15,920,000 $9,783,000 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $18,509,000 -$15,225,000 -464% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $10,838,000 +$12,151,000 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $1,534,000 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q3 2023 $3,284,000 +$3,869,000 +54% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $1,313,000 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q3 2022 $7,153,000 +$383,000 +5.1% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q3 2021 $7,536,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $5,625,000 -$3,341,000 -146% 01 Mar 2021 31 May 2021 10-Q 14 Jul 2021 2021 Q3
Q1 2021 $4,608,000 -$920,000 -25% 01 Dec 2020 28 Feb 2021 10-Q 13 Apr 2021 2021 Q2
Q2 2020 $2,284,000 +$1,788,000 +44% 01 Mar 2020 31 May 2020 10-Q 14 Jul 2021 2021 Q3
Q1 2020 $3,688,000 -$287,000 -8.4% 01 Dec 2019 29 Feb 2020 10-Q 13 Apr 2021 2021 Q2
Q2 2019 $4,072,000 +$282,000 +6.5% 01 Mar 2019 31 May 2019 10-Q 10 Jul 2019 2019 Q3
Q1 2019 $3,401,000 -$485,000 -17% 01 Dec 2018 28 Feb 2019 10-Q 10 Apr 2019 2019 Q2
Q3 2018 $12,727,000 $2,926,000 -$230,000 -8.5% 01 Jun 2018 31 Aug 2018 10-K 27 Nov 2019 2019 FY
Q2 2018 $12,497,000 $4,354,000 -$2,389,000 -122% 01 Mar 2018 31 May 2018 10-Q 10 Jul 2019 2019 Q3
Q1 2018 $10,108,000 $2,916,000 +$267,000 +8.4% 01 Dec 2017 28 Feb 2018 10-Q 10 Apr 2019 2019 Q2
Q4 2017 $10,375,000 $2,531,000 -$295,000 -13% 01 Sep 2017 30 Nov 2017 10-Q 11 Jan 2018 2018 Q1
Q3 2017 $10,080,000 $2,696,000 +$9,501,000 +78% 01 Jun 2017 31 Aug 2017 10-K 27 Nov 2019 2019 FY
Q2 2017 $19,581,000 $1,965,000 -$3,961,000 -198% 01 Mar 2017 31 May 2017 10-Q 12 Jul 2018 2018 Q3
Q1 2017 $15,620,000 $3,183,000 -$1,365,000 -75% 01 Dec 2016 28 Feb 2017 10-Q 09 Apr 2018 2018 Q2
Q4 2016 $14,255,000 $2,236,000 -$4,626,000 -194% 01 Sep 2016 30 Nov 2016 10-Q 11 Jan 2018 2018 Q1
Q3 2016 $9,629,000 $12,197,000 01 Jun 2016 31 Aug 2016 10-K 28 Nov 2018 2018 FY
Q2 2016 $1,996,000 01 Mar 2016 31 May 2016 10-Q 06 Jul 2017 2017 Q3
Q1 2016 $1,818,000 01 Dec 2015 29 Feb 2016 10-Q 05 Apr 2017 2017 Q2
Q4 2015 $2,390,000 01 Sep 2015 30 Nov 2015 10-Q 11 Jan 2017 2017 Q1
Q1 2014 $4,382,465 $1,114,842 +$111,032 +9.1% 01 Dec 2013 28 Feb 2014 10-Q 10 Apr 2014 2014 Q2
Q4 2013 $4,271,433 $1,124,320 -$165,567 -17% 01 Sep 2013 30 Nov 2013 10-Q 14 Jan 2014 2014 Q1
Q3 2013 $4,437,000 $7,877,968 +$9,117,709 01 Jun 2013 31 Aug 2013 10-K 25 Nov 2015 2015 FY
Q2 2013 $4,680,709 $1,256,341 -$705,976 -128% 01 Mar 2013 31 May 2013 10-Q 17 Jul 2013 2013 Q3
Q1 2013 $3,974,733 $1,225,874 -$240,499 -24% 01 Dec 2012 28 Feb 2013 10-Q 10 Apr 2014 2014 Q2
Q4 2012 $3,734,234 $958,753 -$480,234 -100% 01 Sep 2012 30 Nov 2012 10-Q 14 Jan 2014 2014 Q1
Q3 2012 $3,254,000 $1,239,741 -$442,721 -56% 01 Jun 2012 31 Aug 2012 10-K 14 Nov 2014 2014 FY
Q2 2012 $2,811,279 $550,365 -$1,007,735 -220% 01 Mar 2012 31 May 2012 10-Q 17 Jul 2013 2013 Q3
Q1 2012 $1,803,544 $985,375 -$342,584 -53% 01 Dec 2011 29 Feb 2012 10-Q 11 Apr 2013 2013 Q2
Q4 2011 $1,460,960 $478,519 +$124,265 +21% 01 Sep 2011 30 Nov 2011 10-Q 26 Dec 2012 2013 Q1
Q3 2011 $1,585,225 $797,020 01 Jun 2011 31 Aug 2011 10-K 12 Dec 2012 2012 FY
Q2 2011 $457,370 01 Mar 2011 31 May 2011 10-Q 12 Jul 2012 2012 Q3
Q1 2011 $642,791 01 Dec 2010 28 Feb 2011 10-Q 04 Apr 2012 2012 Q2
Q4 2010 $602,784 01 Sep 2010 30 Nov 2010 10-Q 12 Jan 2012 2012 Q1

ORAMED PHARMACEUTICALS INC. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $15,920,000 -$21,008,000 -413% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $5,088,000 +$42,752,000 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $37,664,000 01 Jan 2022 31 Dec 2022 10-K 06 Mar 2024 2023 FY
2020 $11,511,000 +$2,544,000 +18% 01 Sep 2019 31 Aug 2020 10-K 24 Nov 2020 2020 FY
2019 $14,055,000 -$1,328,000 -10% 01 Sep 2018 31 Aug 2019 10-K 24 Nov 2020 2020 FY
2018 $12,727,000 -$2,647,000 -26% 01 Sep 2017 31 Aug 2018 10-K 27 Nov 2019 2019 FY
2017 $10,080,000 -$451,000 -4.7% 01 Sep 2016 31 Aug 2017 10-K 27 Nov 2019 2019 FY
2016 $9,629,000 -$2,396,000 -33% 01 Sep 2015 31 Aug 2016 10-K 28 Nov 2018 2018 FY
2015 $7,233,000 -$1,541,000 -27% 01 Sep 2014 31 Aug 2015 10-K 29 Nov 2017 2017 FY
2014 $5,692,000 -$10,129,000 -228% 01 Sep 2013 31 Aug 2014 10-K 25 Nov 2016 2016 FY
2013 $4,437,000 +$7,691,000 01 Sep 2012 31 Aug 2013 10-K 25 Nov 2015 2015 FY
2012 $3,254,000 -$1,668,775 -105% 01 Sep 2011 31 Aug 2012 10-K 14 Nov 2014 2014 FY
2011 $1,585,225 01 Sep 2010 31 Aug 2011 10-K 12 Dec 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.